


EXAMINER'S AMENDMENT

~~Claim Summary~~

1 – 11 (canceled)

<sup>1</sup>  
~~12.~~ (currently amended) A compound of the formula (I):



wherein

R<sup>1</sup> is alkyl having 1 to 4 carbons or halogen;

R<sup>2</sup> is alkyl having 1 to 4 carbons;

R<sup>3</sup> is hydrogen or hydroxy; and

A is oxygen or ~~C(R<sup>4</sup>)(R<sup>5</sup>);~~

~~R<sup>4</sup> is alkyl having 1 to 4 carbons or hydrogen; and~~

~~R<sup>5</sup> is alkyl having 1 to 4 carbons or hydroxy;~~

or a pharmaceutically acceptable salt thereof.

<sup>2</sup>  
~~13.~~ (previously presented) The compound of claim 12, wherein R<sup>1</sup> is halogen.

<sup>3</sup>  
~~14.~~ (previously presented) The compound of claim 12, wherein R<sup>2</sup> is alkyl having 1 to 2 carbons.

<sup>4</sup>  
~~15.~~ (previously presented) The compound of claim 13, wherein R<sup>2</sup> is alkyl having 1 to 2 carbons.

<sup>5</sup>  
~~16~~. (previously presented) The compound of claim <sup>1</sup>~~12~~, wherein R<sup>3</sup> is hydroxy.

<sup>6</sup>  
~~17~~. (previously presented) The compound of claim <sup>2</sup>~~13~~, wherein R<sup>3</sup> is hydroxy.

<sup>7</sup>  
~~18~~. (previously presented) The compound of claim <sup>4</sup>~~15~~, wherein R<sup>3</sup> is hydroxy.

19. (canceled)

20. (canceled)

21. (canceled)

<sup>8</sup>  
~~22~~. (currently amended) A compound selected from:

5-chloro-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

5-chloro-6-ethyl-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-5,6-dimethyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

5-bromo-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; or

5-fluoro-*N*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

5-fluoro-*H*-({1-[(4-hydroxytetrahydro-2*H*-pyran-4-yl)methyl]piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

5-chloro-*N*-({1-(cyclohexylmethyl)piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; or

5-chloro-*N*-({1-[(1-hydroxycyclohexyl)methyl]piperidin-4-yl)methyl}-1-isopropyl-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

or a pharmaceutically acceptable salt thereof.

<sup>9</sup>  
~~23~~. (previously presented) A pharmaceutical composition comprising a compound of claim <sup>1</sup>~~12~~ or a pharmaceutically acceptable salt thereof together with at least one pharmaceutically acceptable carrier.

24. (canceled)

/CC/  
11/19/09

<sup>10</sup>  
~~25.~~ (previously presented) A method for treating gastroesophageal reflux disease, ~~gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, and gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, diabetes, apnea syndrome, cardiac failure, or heart arrhythmia~~ comprising administering to a mammal in need of such treatment a therapeutically effective mount of a compound according to claim <sup>1</sup>~~12~~ or a pharmaceutically acceptable salt thereof.

<sup>11</sup>  
~~26.~~ (previously presented) A method for treating gastroesophageal reflux disease comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to claim <sup>1</sup>~~12~~ or a pharmaceutically acceptable salt thereof.